Many Asia-Pacific cannabis producers aiming for the lucrative European market, particularly Germany, often misinterpret the stringent EU-Good Manufacturing Practice (EU-GMP) requirements, focusing too heavily on cultivation standards rather than the full supply chain. Successfully exporting cannabis to Europe hinges on meeting the meticulous demands of European importing manufacturers and, crucially, the approval of their Qualified Person (QP), who holds ultimate legal responsibility for batch release.
The global cannabis industry continues its rapid expansion, with producers across the Asia-Pacific region, including nations like Thailand and Australia, significantly scaling up cultivation efforts. While Good Agricultural and Collection Practice (GACP) certification is a vital first step for raw material production, it represents only one part of the complex puzzle for market entry into the European Union. The regulatory landscape in Europe, particularly in Germany, demands a comprehensive understanding of GMP beyond the farm gate, influencing everything from post-harvest processing to final product release.
The EU-GMP Challenge for Asia-Pacific Producers
For many Asia-Pacific cannabis cultivators, the conversation around European market access frequently begins and ends with the grow room: licences, GACP certificates, genetics, and yield metrics. They often observe the strong demand from German pharmacies, tally their certified GACP capacity, and view subsequent regulatory steps as mere “paperwork.” However, this perspective overlooks a critical reality: whether a cannabis batch ever reaches a European patient is ultimately decided within Europe itself, by a single individual – the Qualified Person (QP) at the importing manufacturer.
This QP carries the full legal responsibility for releasing each batch into the European market. Consequently, any export strategy that prioritizes an origin-country certificate over what this European QP requires for their signature is fundamentally misaligned. The focus must shift from merely possessing a certificate to understanding and implementing the entire chain of custody and processing that will satisfy European regulatory bodies and, most importantly, the QP.
Thailand’s Export Landscape and EU Access
Thailand, for example, has made significant strides in building its cannabis cultivation capacity. As of February 2026, the Department of Thai Traditional and Alternative Medicine (DTAM) listed 217 certified GACP growing sources, representing a robust domestic production base. Dr. Peeracha Kuekasemkit, head of DTAM’s medical cannabis division, reported in July 2026 that Thailand’s cannabis and hemp exports reached 2.5 billion Thai Baht (THB) across 31 countries. Australia stands as the largest market, with European buyers including Germany, Czechia, Switzerland, and Portugal.
Despite these impressive export figures and GACP certifications, a crucial gap remains: not a single Thai cannabis site is listed in EudraGMDP, the EU’s official database of GMP certificates. This absence is significant because Thailand does not have a mutual recognition agreement with the EU for pharmaceutical standards. This means that while Thai cannabis is being exported to Europe, it is not entering the market directly as a fully GMP-certified product from its origin, necessitating specific import pathways and further processing within Europe.
Germany’s Stricter Interpretation of GMP Steps
The primary route for non-EU-GMP cannabis to enter Germany has been via Annex 7 of the EU-GMP guidelines. This provision permits initial cutting and drying of cannabis in the field under GACP, provided the marketing authorization justifies it. However, any subsequent cutting, drying, or other processing steps are expected to fall under GMP. Many supply chains have interpreted this provision broadly, conducting drying and trimming under GACP at the origin, shipping the material, and completing the “finishing” job under GMP once it arrives in Europe.
This interpretation was challenged by a significant ruling on June 8, 2026. The Hessian State Office for Health and Care (HLfGP) in Germany explicitly rejected this generous reading, as reported by Business of Cannabis. Inspectors from the HLfGP discovered that GMP-level processing steps were being carried out at sites that lacked proper GMP certification. This guidance from Hesse carries immediate implications for importers:
- Every import application must now include a detailed scheme, outlining supplier by supplier and site by site, precisely which steps are conducted under GACP and which under GMP.
- Importers holding existing authorizations are now required to review their current processes and submit a comprehensive gap analysis.
The Hessian ruling is not an isolated incident. When the German cannabis industry publication Krautinvest.de surveyed other German state regulators in July 2026, the majority indicated that they either shared the HLfGP’s view or arrived at the same conclusion regarding GMP compliance. While Saxony and Saxony-Anhalt expressed a preference for case-by-case decisions, and Bavaria did not provide a response, the overall sentiment points towards a unified, stricter interpretation across Germany.
The combined effect of this guidance is clear: it does not abolish the raw-material import route, but it significantly narrows what can still be classified as “raw material.” If drying and trimming are now considered GMP steps, then cannabis flower that has already undergone these processes abroad is, by definition, already a GMP product. To enter Germany, such a product would then require a section 72a certificate, which practically necessitates a direct German inspection of the origin site to verify GMP compliance. Therefore, any producer wishing to continue shipping flower to Germany must plan for GMP-grade drying and trimming directly at the cultivation facility and anticipate an inspection from German authorities.
The Role of the Qualified Person
At the heart of European pharmaceutical regulation, and specifically cannabis imports, is the Qualified Person (QP). This individual, typically a pharmacist or other qualified professional, is legally responsible for ensuring that each batch of medicinal product, including cannabis, meets all the requirements of the marketing authorisation, EU-GMP, and any other relevant legislation before it is released for sale or supply. Their signature is the final gatekeeper for market access. Producers who make the QP’s decision-making process straightforward and fully compliant will find a much clearer path to European buyers. This emphasis on the QP highlights the need for transparency, meticulous documentation, and adherence to European standards throughout the entire supply chain, not just at the point of cultivation. For more on the complexities of European cannabis regulations, consider reading about Germany’s medical cannabis reimbursement challenges.
Navigating the Regulatory Labyrinth
The stricter interpretation of GMP steps by German regulators underscores the need for APAC producers to reverse their planning process. Instead of starting at the farm and hoping to meet European standards, they should begin with the European batch release decision and work backward. This “QP-first” approach ensures that every step in the cultivation, harvest, and post-harvest process is designed to satisfy the ultimate requirements of the European importer and regulator.
Australian Model and Mutual Recognition
In contrast to Thailand, Australia possesses a mutual recognition agreement with the EU. According to the European Medicines Agency, this agreement encompasses herbal medicines produced in Australia, provided they are classified as medicinal products. Such agreements allow EU authorities to rely on the partner country’s GMP inspections and can even waive the need for batch testing upon import. This significantly streamlines the import process by addressing the inspection question at the source.
However, even with a mutual recognition agreement, other regulatory considerations remain. It is an open legal question whether guidance such as the one issued by Hesse applies in full to products certified under such agreements. This suggests that while mutual recognition simplifies certain aspects, producers must still remain vigilant about evolving interpretations of GMP rules within individual European jurisdictions. Understanding these nuanced national requirements is crucial for consistent market access, a challenge that also affects other aspects of the European market, such as UK employers’ duty of care for medical cannabis patients.
The Asia-Pacific region clearly has no shortage of cannabis cultivation capacity. The decisive factor for market access into Europe is whether a European Qualified Person can confidently stand behind the release of a product. Producers who proactively structure their entire operation, from seed to processing, to facilitate that decision will undoubtedly be the ones who secure and maintain buyers in the demanding but rewarding European medical cannabis market. This requires a deep understanding of not just cultivation, but also the pharmaceutical standards and regulatory expectations that govern medicinal product supply chains.
Frequently Asked Questions
What is the main challenge for Asia-Pacific cannabis producers exporting to Europe?
The primary challenge is often a misunderstanding of EU-GMP requirements, focusing too much on GACP cultivation and not enough on the full supply chain compliance needed for European market entry, especially the Qualified Person’s approval.
Why is EU-GMP certification critical for European cannabis market access?
EU-GMP certification ensures that cannabis products meet stringent pharmaceutical quality standards, which is a mandatory requirement for medicinal products to be legally sold and supplied in the European Union.
How does Germany interpret Good Manufacturing Practice (GMP) for imported cannabis?
German regulators, exemplified by the Hessian State Office, have adopted a stricter interpretation, classifying post-harvest steps like drying and trimming as GMP activities. This means such processes must occur at GMP-certified sites, potentially requiring German inspections at the origin.
What is the role of a Qualified Person in European cannabis imports?
A Qualified Person (QP) at the importing manufacturer is legally responsible for verifying that each batch of medicinal cannabis meets all EU-GMP and regulatory standards before it is released for distribution within the European market.
Does a mutual recognition agreement simplify cannabis exports to the EU?
Yes, mutual recognition agreements, such as Australia’s with the EU, can simplify exports by allowing EU authorities to rely on the partner country’s GMP inspections and potentially waive batch testing upon import, though specific jurisdictional guidance may still apply.
What steps should APAC producers take to ensure EU market access?
APAC producers should adopt a “QP-first” strategy, planning their entire cultivation and processing chain to meet European GMP standards and requirements, anticipating potential site inspections, and ensuring meticulous documentation.
